NMRA•benzinga•
B of A Securities Downgrades Neumora Therapeutics to Underperform, Lowers Price Target to $1
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 2, 2025 by benzinga